CX 趋化因子及其受体在癌症中的新作用。

The emerging role of CXC chemokines and their receptors in cancer.

机构信息

Institute of Cancer Therapeutics, Tumbling Hill Street, Bradford, BD7 1DP, UK.

出版信息

Future Med Chem. 2012 May;4(7):853-67. doi: 10.4155/fmc.12.48.

DOI:10.4155/fmc.12.48

Abstract

Chemokines and their receptors have a multifaceted role in tumor biology and are implicated in nearly all aspects of cancer growth, survival and dissemination. Modulation of the interaction between chemokines and their cell surface receptor is, therefore, a promising area for the development of new cancer medicines. In this review, we look at the compelling evidence that is emerging to support targeting CXC chemokines, also known as family α chemokines, as novel therapeutic strategies in the treatment of cancer.

摘要

趋化因子及其受体在肿瘤生物学中具有多方面的作用，并与癌症生长、存活和扩散的几乎所有方面都有关联。因此，调节趋化因子与其细胞表面受体之间的相互作用是开发新型癌症药物的一个很有前景的领域。在这篇综述中，我们着眼于越来越多的有力证据，这些证据支持将 CXC 趋化因子（也称为家族 α 趋化因子）作为治疗癌症的新型治疗策略。